Research / LLY
Eli Lilly Hold
Cumulative score 3.0 · the model has rated LLY Hold since Jul 15, 2026 · 18 active of 143 total events · Healthcare
Automated research experiment, not investment advice. An AI model scores public information; a formula flips ratings. It can be wrong, late, or stale. I may hold positions. Do your own research.
The model rates Eli Lilly Hold, reflecting a near-balanced score where competitive losses in oral obesity drugs have largely offset pipeline and analyst positives. The most consequential headwind is Novo Nordisk's oral Wegovy capturing roughly 89% of U.S. weekly prescriptions versus Lilly's approximately 11%, a significant share gap in what was expected to be a key new category, compounded by EU regulatory approval of oral Wegovy across all member states. A revived Teva lawsuit over an alleged settlement violation adds a credible legal overhang. Positive developments such as an earnings beat, meaningful oral GLP-1 share recovery, or resolution of the legal risk would be needed to shift the model toward Buy.
Written Jul 15, 2026, when the rating was Hold. Rewritten automatically each time the rating flips.
Score history
Daily cumulative score. The model enters Buy above +5.0, Strong Buy above +7.5, and Sell below -5.0; each tier exits at a looser threshold so ratings don't flap.
Rating changes
Triggered by: Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions · NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart · U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement Agreement
Triggered by: RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1500 · Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says · Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover
Event history
Every informational event the model has scored for LLY, newest first, with its reasoning and what each event still contributes to the score today.
European Stocks Close Higher in Tuesday Trading; Investors Await ECB Rate Decision
Unscored after 3 attempts.
Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising
Unscored after 3 attempts.
Novo sues Lilly after alleged misleading and false advertising campaign
Unscored after 3 attempts.
Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns
Unscored after 3 attempts.
Sector Update: Healthcare Stocks Advance Tuesday Afternoon
Unscored after 3 attempts.
AbbVie Stock Zigs When The Market Zags
Unscored after 3 attempts.
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Unscored after 3 attempts.
Sector Update: Healthcare Stocks Rise Late Afternoon
Unscored after 3 attempts.
Eli Lilly Stock And The Price Of Confidence
Unscored after 3 attempts.
Top Research Reports for Eli Lilly, Costco & Morgan Stanley
Unscored after 3 attempts.
Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads
Unscored after 3 attempts.
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.
Unscored after 3 attempts.
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
Unscored after 3 attempts.
‘Wild West’ of Untested Peptides Has Americans Paying in Crypto to Get Their Fix
Unscored after 3 attempts.
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside
Unscored after 3 attempts.
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
Unscored after 3 attempts.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Unscored after 3 attempts.
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
Unscored after 3 attempts.
Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum
Unscored after 3 attempts.
Eli Lilly Stock And The Price Of Confidence
Unscored after 3 attempts.
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?
Unscored after 3 attempts.
Reading Between The Lines Of JNJ Stock's Latest Call
Unscored after 3 attempts.
Sector Update: Healthcare Stocks Fall Late Afternoon
Unscored after 3 attempts.
Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase
Unscored after 3 attempts.
Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings
Valuation opinion piece using public DCF; no new facts, no rating change, no price target move.
Our Top 10 High Growth Dividend Stocks - July 2026
Dividend stock list article; no new LLY-specific information.
3 Biggest Pharma Giants: Buy, Sell or Hold?
Generic multi-stock opinion piece with no new LLY-specific facts or rating changes.
Fat cat? Weight-loss drugs may be coming for your overweight pet
Speculative early-stage discussion of GLP-1 for pets; no LLY-specific program or data disclosed.
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
Positive opinion piece on LLY's pipeline breadth beyond GLP-1; no new factual information.
AI Bubble Risks Make Dividend Stocks Attractive Again
General macro/dividend thematic piece; LLY not specifically featured.
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Viking Therapeutics entering Phase testing with a beyond-GLP-1 weight loss drug is a credible competitive threat to LLY's Zepbound franchise, though early-stage.
The Real Question Buried Inside Merck Stock's Premium Price
Article is about Merck valuation; no relevance to LLY.
Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup
Quantitative stock-screen article on LLY momentum; no new fundamental or event-driven information.
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
Fund marketing PR touting their LLY entry price; no new information about LLY as a company.
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
Jefferies frames AtaiBeckley acquisition as part of a positive Big Pharma psychedelics trend; incremental analyst color on an already-known deal.
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives
Third mention of AtaiBeckley deal in a deal-dispatch roundup; same fact, scores 0 per repeat rule.
Prozac Maker Eli Lilly Just Bought a Psychedelics Company for $2.8 Billion — Here’s What It Could Mean for Mental Health
Second story on the AtaiBeckley acquisition already scored via fa59ffe6ddceed85; same underlying fact.
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
Abivax M&A speculation does not name LLY as a party; not LLY-specific news.
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY acquires AtaiBeckley for $2.8B upfront ($3.8B total) to enter psychedelic therapy; meaningful pipeline expansion into a new area.
Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says
UBS argues LLY's GLP-1 franchise faces limited generic threat; modestly positive clarification for long-term holders.
Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
Price action and buy-zone commentary; no new fundamental information beyond the AtaiBeckley deal already covered elsewhere.
IPO Stock Of The Week: This Eli Lilly Partner Soars 118% In Three Months
LLY partner Omada up 118% suggests GLP-1 ecosystem validation, but indirect and speculative benefit for LLY.
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win
Novo Nordisk oral Wegovy pill launch is a competitive GLP-1 threat to LLY, though article argues LLY can still win; rumor cap not applicable but competitive risk is real and partially known.
Sector Update: Healthcare Stocks Mixed Late Afternoon
Sector-level healthcare stock update with no LLY-specific content.
If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today
Historical return retrospective; no new information, pure PR fluff.
Dell Stock Lit The Afterburners. Is There Enough Fuel For The Trip?
Dell stock story; irrelevant to LLY.
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
AstraZeneca oncology update; no LLY-specific information.
Shares of several banks and financial services companies are trading higher amid overall market strength as investors anticipate this week's Fed Reserve meeting.
Banking/Fed headline; no LLY relevance.
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
LLY milestone payment to VivoSim confirms drug candidate advanced to Phase 2, minor confirmatory signal of pipeline progress.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Biogen competitor setback; marginal indirect benefit to LLY but not LLY-specific news.
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Roche/RHHBY FDA news; no direct LLY impact described.
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Generic sector index move, no LLY-specific information.
NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
EU regulatory approval of oral Wegovy across all member states is a distinct new milestone extending Novo's competitive lead over LLY in a major market.
Sector Update: Healthcare Stocks Advance Late Afternoon
Broad healthcare sector advance; no LLY-specific content.
Lilly's Obesity Pill Trails Wegovy
Second story on same Wegovy vs. LLY oral pill prescription share data; same underlying fact already scored.
Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions
Lilly's oral obesity pill capturing only ~11% of weekly prescriptions vs Wegovy's 89% is a significant competitive loss in LLY's key new product category.
Federal Health Watchdog Projects $5.56 Billion in Recoveries and Savings, Despite Enforcement Hitting Two-Year Low
HHS enforcement/savings projection is broad sector news with no identified LLY-specific exposure.
Sofinnova Partners Appoints David Evans as Partner
Sofinnova Partners VC hire; unrelated to Eli Lilly.
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors
Rehash of the well-known fact that GLP-1 drugs drive ~two-thirds of LLY revenue; no new information.
Capital Square Fully Subscribes Richmond Active-Adult DST Offering
Real estate DST offering fully subscribed; completely unrelated to Eli Lilly.
How Does LLY Stock Reach $2,100?
Valuation opinion piece projecting LLY to $2,100; no new factual information, scores based on underlying facts not hype.
Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week
Same ARK/Cathie Wood LLY purchase story already captured in d4d97f0f; second story on same fact scores 0.
U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement Agreement
U.S. Appeals Court revived Teva's lawsuit against Lilly for alleged settlement agreement violation; reinstatement of a previously dismissed case is a credible incremental legal risk.
Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group
ARK Invest adding LLY to portfolio is a minor positive signal from a named institutional buyer, though Cathie Wood purchases rarely move fundamentals.
Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher
Speculative opinion piece about an unnamed pipeline catalyst; no confirmed new data, hype language penalized.
Macro Note: The Tech Unwind Grew A Second Leg, And It's Healthcare
Sector-rotation narrative into healthcare is too broad and macro to assign a company-specific score to LLY.
Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC
LLY announcing new Kisunla long-term data and P-tau217 blood-test progress at AAIC is a concrete pipeline update, though the actual data results are not yet disclosed.
Should You Buy Eli Lilly Stock? Here's My Honest Take.
Opinion/analysis piece with no new data or rating change; rehashes known bull and bear cases.
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026
Generic dividend-stock listicle; no LLY-specific new information.
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
Pfizer's long-acting GLP-1 program is still speculative and unproven; article explicitly frames them as an also-ran, making competitive threat to LLY negligible at this stage.
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
Zacks aggregator blog listing LLY among several biotech names with no new rating or target specific to LLY.
Top Funds Bet Big On 19 Stocks — Including Eye-Popping Sums On These Five
Secondary-source article summarizing already-public 13F filings showing LLY as one of 19 fund buys; no new information.
JNJ Stock Keeps Climbing. Should You Climb On?
Johnson & Johnson stock article; not about Eli Lilly.
6 Health Care Stocks With Whale Alerts In Today’s Session
Options whale-alert roundup listing LLY among six healthcare names; no fundamental new information.
B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334
BofA maintains Buy and raises LLY price target from $1251 to $1334; incremental positive from a major bank, though routine in current GLP-1 upcycle.
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
NVO monthly rally driven by UK Wegovy approval is mild competitive context; does not materially shift LLY's GLP-1 thesis given overall market expansion.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Biotech sector rout article focused on Moderna/ImmunityBio/Sarepta; LLY not mentioned and GLP-1 segment unaffected.
Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%
ETF allocation article; no new facts about Lilly's fundamentals or outlook.
Stocks Look Shaky, But This Sector is Booming (Biotech)
Sector roundup mentioning LLY in passing; no company-specific new information.
/C O R R E C T I O N -- Eli Lilly and Company/
Routine conference abstract announcement for AAIC; no data readout or surprise, consistent with Lilly's long-running Alzheimer's program.
Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma
Retrospective market-cap recap; no new company-specific information.
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
PR fluff rehashing well-known GLP-1 demand growth story; no new facts about Lilly specifically.
Schrödinger: Surviving, If Not Thriving, In The Tricky AI Drug Discovery Field
Schrödinger (SDGR) analysis; no LLY content.
The Wide Divide Ahead For Eli Lilly Stock
Scenario opinion piece on LLY stock outcomes; no new factual disclosure.
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
Speculative opinion on AI/biology convergence opportunity; no new factual disclosure about LLY.
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
Morgan Stanley broad biopharma sector view; 'driven by fundamentals' is neutral and not LLY-specific.
Sector Update: Healthcare Stocks Lower Wednesday Afternoon
Routine healthcare sector index decline update; no LLY-specific event.
Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly
LLY mentioned among market movers with no specific fact disclosed.
Is It Too Late to Buy Eli Lilly?
Valuation opinion on LLY; no new factual disclosure.
Texas Instruments Stock Is Running On A Bold Promise
Texas Instruments article; no LLY content.
Sector Update: Healthcare Stocks Decline Late Afternoon
Routine sector index decline update; no LLY-specific event.
Why Eli Lilly Stock Climbed to a Record High Today
Price action recap following RBC upgrade already scored; second story on same fact.
Top 50 High-Quality Dividend Growth Stocks For July 2026
Generic dividend growth stock list; no LLY-specific analysis.
RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1500
RBC raises LLY price target 20% from $1250 to $1500, maintaining Outperform; a notable single-analyst move ahead of earnings.
Stocks To Watch: 14 Names Test And Tease New Buy Zones
Generic multi-stock watchlist; no LLY-specific analysis.
Dow Jones Futures Tumble, Oil Prices Soar As Trump Says U.S.-Iran Ceasefire 'Over'
Duplicate of US-Iran ceasefire story already scored above.
Dow Jones Futures Fall, Oil Prices Soar As Trump Says U.S.-Iran Ceasefire 'Over'
US-Iran geopolitical macro headline; no direct material impact on LLY.
This $1,200 Stock Could Be the Next Massive Stock Split Opportunity
Stock split speculation referencing already-known Q1 results; no new information.
Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026
Speculative year-end price prediction article; no new factual content.
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
Price action commentary on record high; no new fundamental information.
Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says
Second RBC article on the same Q2 beat expectation already scored above; scores 0 per repeat rule.
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
Morgan Stanley sector rotation thesis for biopharma H2; not LLY-specific.
Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says
RBC pre-earnings call expecting Q2 revenue beat on GLP-1 volume; positive but unconfirmed pre-announcement.
Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover
Two concrete business moves: new Abbisko R&D collaboration and Verzenios China rights transfer to Innovent; real events but neither is material to LLY revenue at scale.
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Article focuses on Novartis pipeline; LLY not the subject.
Can anyone catch up to Eli Lilly?
Competitive positioning opinion piece on LLY; no new product, guidance, or analyst action.
Andrew Hill Investment Advisors' Q2 2026 Significant Positions
Fund quarterly position recap article; no new LLY-specific information.
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Altimmune upgrade article; competitor catalyst is very indirect and minor for LLY.
The Zacks Analyst Blog Highlights Eli Lilly, HSBC, Palantir and CBL & Associates
Zacks blog roundup of existing research; no new rating or target change identified.
Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.
Opinion/valuation article on LLY; no new analyst action or fundamental information.
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
Article compares Pfizer and AstraZeneca; LLY not the subject.
Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?
Valuation opinion piece on LLY all-time high; no new analyst action, price target, or fundamental data.
Lilly quietly hands Chinese partner its cancer drug
LLY transferred full China rights for a cancer asset to a local partner; minor business development event in a non-core segment.
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1350
Cantor raises LLY PT from $1230 to $1350; single analyst nudge upward, no rating change.
Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.)
Bullish opinion piece with no new facts; headline hype, not informational surprise.
Cramer’s Mad Dash: iShares Biotechnology ETF
Cramer segment on biotech ETF; no LLY-specific content discernible from summary.
My Top 5 Pharma Stocks Wall Street Ignores
Pharma listicle; no LLY-specific new information.
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
Long-horizon promotional opinion piece; no new facts.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Search-popularity article; zero informational content about LLY fundamentals.
8 Health Care Stocks With Whale Alerts In Today’s Session
Options flow alert across sector; no company-specific information.
Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges
Q1 fund letter recap; regulatory and pricing headwinds already known and priced in.
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
AbbVie earnings preview; no new information about LLY.
Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says
About Abivax/obefazimod; not materially relevant to LLY's thesis.
Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings
Article is about J&J, not LLY; appears in LLY feed incidentally.
Lilly, This IPO Leader Among Stocks To Watch In A Mischievous Market
Market watch watchlist piece; no new information specific to LLY.
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Valuation-comparison opinion piece; no new facts, just a restatement of known metrics.
3 Healthcare ETFs to Own in a Choppy Stock Market
Generic ETF listicle; LLY is incidental context, not the subject of new information.
What Eli Lilly Stock Said When It Had Too Much Business
Retrospective narrative piece with no new facts; pure storytelling about a historical period already known to investors.
Top Stock Reports for Eli Lilly, HSBC & Palantir
Generic Zacks analyst roundup; no new rating, target, or fundamental data for LLY.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Routine daily price-movement article with no new fundamental information.
Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premium
Valuation screen analysis; no new fundamental facts, just ratio commentary.
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
Viking Therapeutics projection piece; competitor context, no new LLY-specific information.
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States
Medicaid/CHIP enrollment politics; broad impact across all pharma with no LLY-specific surprise.
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
J&J exiting obesity market is already well-known; no new competitive surprise for LLY.
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For July 2026
Dividend strategy screen; LLY appears incidentally, no new information.
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying
Viking Therapeutics bull/bear piece; no new LLY-specific information.
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
JNJ vs LLY comparison; Q1 results and raised guidance already reported and known.
[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Market research report press release; industry-size projections are promotional, not primary-source news.
HIMS Breakout Signals Structural Business Transformation
Hims & Hers turnaround narrative; compounded GLP-1 risk to LLY is already well-known, no new fact here.
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Medicare GLP-1 Bridge benefits NVO primarily; no incremental surprise for LLY's competitive position.
8 Health Care Stocks Whale Activity In Today’s Session
Options flow sector alert; no LLY-specific actionable content.
Here's Why Viking Therapeutics Stock Surged Higher in June
Viking June recap; past performance rehash, no new LLY-relevant information.
Takeda deal lets us scale our capabilities: Insilico Medicine CEO
Insilico/Takeda AI drug-discovery deal; not directly relevant to LLY.
News data via Finnhub. Filings via SEC EDGAR. Scores are model states, not recommendations.